Employees: 133
Size MapLight Therapeutics (MPLT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $370M, the 2906th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.65 on 18 Nov 2026.
Performance Over six months the shares fell 76.1%, against -23.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.
Capital Return on invested capital runs 149.0 points below its cost of capital (20.0% WACC).
Short interest Short interest is 5.8% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$584,000 | -$578,000 | -$701,000 | -$556,000 | -$574,000 |
| EBITDA | -$266M | -$169M | -$82.2M | -$56.7M | -$30.7M |
| Net income | -$252M | -$161M | -$77.6M | -$55.7M | -$30.0M |
| Free cash flow | -$179M | -$139M | -$79.6M | -$52.5M | -$27.3M |
| Capital expenditure | $434,000 | $473,000 | $770,000 | $462,000 | $746,000 |
| Total debt | $1.69M | $5.80M | $6.58M | $5.92M | $6.27M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MPLT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.3% | -13.3% | 4th lowest of 20 |
| 6-month return | -76.1% | -23.2% | lowest of 19 |
| Distance from 52-week high | -83.5% | -38.5% | lowest of 21 |
| ROIC minus cost of capital | -149.0 pp | -6.6 pp | 2nd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 3.0× | -7.9% | +24.8% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | 5.3× | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | 1.6× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 0.5× | 6.7% | +4.2% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | 1.1× | 3.6% | +3.1% |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |